Abstract
Glaucoma is a progressive, irreversible loss of retinal ganglion cells (RGCs) and axons that results in characteristic optic atrophy and corresponding progressive visual field defect. The exact mechanisms underlying glaucomatous neuron loss are not clear. The main risk factor for glaucoma onset and development is high intraocular pressure (IOP), however traditional IOP-lowering therapies are often not sufficient to prevent degeneration of RGCs and the vision loss may progress, indicating the need for complementary neuroprotective therapy. This review summarizes the progress for neuro protection in glaucoma in recent 5 years, including modulation of neuroinflammation, gene and cell therapy, dietary supplementation, and sustained-release system.
Introduction
Glaucoma is a progressive, irreversible loss of retinal ganglion cells (RGCs) and axons that results in a characteristic optic atrophy and a corresponding progressive visual field defect. The most common types of glaucoma are primary open-angle glaucoma and primary angle closure glaucoma (PACG) (Dietze et al., 2022). Acute PACG has typical anatomical characteristics, such as shallow anterior chamber, pupillary block, plateau iris, etc., it usually causes acute attack. However, patients with POAG and chronic PACG are often asymptomatic until the optic nerve damage is severe. The exact mechanisms underlying glaucomatous neuron loss are not clear.
Although some scholars believe that it is a neurodegenerative disease (Ramirez et al., 2017), it is not exactly the same as Parkinson’s disease, Alzheimer’s disease, and other neurodegenerative diseases that mainly occur in the middle-aged and the elderly. Glaucoma has a wide age, some young and middle-aged patients with open and chronic closure have very late visual field, obvious C/D cupping and optic nerve atrophy. Because irreversible blindness seriously affects patients’ quality of life and heavy social burden, it is critical to explore the possible pathogenesis of optic nerve injury and effective treatment targets.
The main risk factor for glaucoma onset and development is high intraocular pressure (IOP), and the current treatments available target the lowering of IOP (Dietze et al., 2022). However, degeneration of RGCs and the vision loss may progress despite significant IOP lowering in some patients, indicating that complementary neuroprotective therapy are needed. In recent years, a large number of studies on optic nerve protection have emerged, this review summarizes the progress for neuro protection in glaucoma in recent 5 years, including modulation of neuroinflammation, gene, and cell therapy, dietary supplementation, and sustained-release system.
Neuroimmunity
Immune system dysregulation is increasingly being attributed to the development of a multitude of neurodegenerative diseases (Stothert and Kaur 2021). In recent years, a large amount of studies focus on the glia cells and immune system in the development of glaucomatous optic neuropathy (de Hoz et al., 2018). An excessive microglial response may be a significant degenerative factor for increased cell death (Grotegut et al., 2020), microglia activation and release of pro-inflammatory cytokines are the main contributors for retinal cell death in glaucoma (de Hoz et al., 2018). OPN was found to enhance the proliferation and activation of retinal microglia, and contribute to the eventual RGCs loss and vision function impairment in glaucoma (Yu et al., 2021). Blocking microglial A2A R prevents microglial cell response to elevated pressure and it is sufficient to protect retinal cells from elevated pressure-induced death (Aires et al., 2019). Another study found activation of Adenosine A (3) receptor could hinder the microglia reactivity (Ferreira-Silva et al., 2020), attenuated the impairment in retrograde axonal transport, and afford protection against glaucomatous degeneration. In addition, P2X7 receptor antagonist protects retinal ganglion cells by inhibiting microglial activation in a rat chronic ocular hypertension model (Dong et al., 2018).
Astrocytes perform critical non-cell autonomous roles following CNS injury that involve either neurotoxic or neuroprotective effects. Astrocyte-derived lipoxins A4 and B4 promote neuroprotection from acute and chronic injury neuroprotective signal (Livne-Bar et al., 2017). Statins promotes the survival of RGCs by reduce apoptosis and suppress chronic high IOP induced glial activation (Kim et al., 2021).
Gene therapy
Gene therapy, which uses a viral vectors to deliver genetic material into cells, is a promising approach to directly target pathogenetic molecules (Keeler et al., 2017). The retina is a favorable target for gene therapy because of its easy access, established clear functional readouts, partial immune privilege and confined non-systemic localization (Ratican et al., 2018). The success of adeno-associated virus (AAV)-mediated gene replacement therapy for inherited retinal disease (Maguire et al., 2008; Busskamp et al., 2010; Smalley 2017) has made RGC-specific gene expression and AAV editing a promising gene therapy strategy for optic neuropathies. Table 1 lists the gene therapy studies on neuroprotection of glaucoma in recent 5 years, their findings indicate that gene therapy has a broad prospect in protecting both structure and function of RGC. Apart from this, reprogramming cells with defined factors is another promising strategy to produce functional cells for therapeutic purposes (Wang et al., 2021). OSK-induced reprogramming in mouse RGC was found to promote axon regeneration and reverse vision loss (Lu et al., 2020). Math5 and Brn3b transcription factors (TFs) combination can reprogram mature mouse Müller glia into RGC, resulting in proper projection of RGC in the visual pathway, and improved visual function (Xiao et al., 2021). Recently, another study, using a CRISPR-Cas9-based genome-wide screen of 1,893 TFs, found that manipulation of ATF3/CHOP and ATF4/C/EBPγ protected RGC in a glaucoma model (Tian et al., 2022).
TABLE 1
| Target gene | Effect | Model | Function | References |
|---|---|---|---|---|
| Complement C3 | overexpression of C3 inhibitor reduce the activation of complement C3d | intravitreal injection in mice glaucoma model | neuroprotection of retinal ganglion cells (RGC) axons and somata | Bosco et al. (2018) |
| Brain-derived neurotrophic factor (BDNF) and its receptor | increase the production of BDNF and TrkB | intravitreal injection in experimental glaucoma or humanized tauopathy model | improve long-term neuroprotective signaling, RGC survival, and functional recovery | Osborne et al., 2018, Wojcik-Gryciuk et al., 2020, Khatib et al., 2021 |
| Vascular endothelial growth factor (VEGF) | transduction of VEGF variants by VEGFR2 and PI3K/AKT signaling | AAV2-mediated transduction into primary mouse RGC | promote synaptogenesis, increase the length of neurites, axons | Shen et al. (2018) |
| γ-synuclein (mSncg) promoter | combine AAV-mSncg promoter with CRISPR/Cas9 gene editing knock down pro-degenerative genes | AAV2-mSncg in hPSC-derived RGCs and mice ON crush model | preserve the acutely injured RGC somata and axons | Wang et al. (2020) |
| CaMKII | increase the expression level of CaMKII | intravitreal injection AAV for the treatment of CaMKIIα T286D in a mouse model of glaucoma | protection of RGC and their axons | Guo et al. (2021) |
| BCLXL | gene therapy with mCherry-BCLXL and force its overexpression | intravitreal injection in mice glaucoma model | robustly attenuate both RGC soma pathology and axonal degeneration in the optic nerve | Donahue et al. (2021) |
| NMNAT | overexpression of NMNAT2 mutant driven by mSncg promoter restore the decreased NAD + levels | intravitreal injection in mice glaucoma model | significant neuroprotection of both RGC soma and axon and preservation of visual function | Fang et al. (2022) |
| Myc-associated protein X (MAX) | gene therapy by overexpression of MAX | intravitreal injection in rat glaucoma model | prevent RGC death and protect optic nerve axons | Lani-Louzada et al. (2022) |
| X-linked inhibitor of apoptosis (XIAP) | blocking the activation of apoptosis | intravitreal injection in mice glaucoma model | provide both functional and structural protection of RGC | Visuvanathan et al. (2022) |
Gene therapy studies on neuroprotection of glaucoma in recent 5 years.
Cell therapy
Cell therapy provides a new therapeutic strategy for glaucoma. Stem cell therapy mainly involves the transplantation of cells to replace the dead and lost RGC. However, it is associated with a number of major challenges besides ethical issue. Regeneration of RGCs requires full synaptic integration of host inner retinal stem cells and the development of long-distance axons, which project to the brain and accurately form effective synaptic connections with corresponding targets to complete signal transmission. Up to now, the replacement of RGCs has not made a breakthrough (Zhang J. et al., 2021). Several recently studied cell types for transplantation including mouse induced pluripotent stem cell (miPSC) or mouse embryonic stem cell (mESC)-derived RGC (Oswald et al., 2021) and spermatogonial stem cell-derived RGC (Suen et al., 2019). Another study found mesenchymal stem cells (MSC) secreted exosomes can promote survival of RGC and regeneration of their axons (Mead and Tomarev 2017). In addition, further study found that TNF-α stimulated gingival MSC derived exosomes play neuroprotection and anti-inflammation roles by delivering miR-21-5p-enriched exosomes through MEG3/miR-21-5p/PDCD4 axis (Yu et al., 2022).
Dietotherapy
In animal models of glaucoma, various diet-related treatments were found as non-IOP-related neuroprotective mechanisms. High VitK1 intake (Deng et al., 2020) , Coenzyme Q10 + Vitamin E (Zhang et al., 2017; Ekicier Acar et al., 2020), Nicotinamide riboside of the vitamin B3 family (Zhang X. et al., 2021), probiotic bacteria (Fafure et al., 2021) and other dietary supplementation (Cammalleri et al., 2020) were proved to attenuate the loss of RGCs by regulating glia-mediated neuroinflammatory or BDNF activity, etc.
New drug loading system
Several preclinical studies demonstrate that neurotrophins (NTs) prevent RGCs loss (Gupta et al., 2022). NTs can be conjugated to nanoparticles, which act as smart drug carriers. This enables the self-localization of drugs in the retina and the prevention of rapid degradation of drugs (Giannaccini et al., 2018).
Sunitinib is a protein kinase inhibitor with activity against the neuroprotective targets dual leucine zipper kinase (DLK) and leucine zipper kinase (LZK). It was found to enhance survival of RGCs for neuroprotection. Recently, a hypotonic, thermosensitive gel-forming eye drop (Kim et al., 2022) and a sunitinib-pamoate complex (SPC) microcrystals for subconjunctival injection (Hsueh et al., 2021) were devised to continuously release for 1 and 20 weeks.
Others
Cannabinoids (CBs) was found to target several factors that related with the progression of glaucoma, it promotes neuroprotection, abrogates changes in ECM protein, and normalizes the IOP levels in the eye (Maguire et al., 2022; Somvanshi et al., 2022).
In summary, various neuroprotective therapy (Figure 1) can help us to better understand the pathological basis of visual function impairment and progression in glaucoma. At present, many scholars have committed to clinical translation to save RGCs and visual function of glaucoma patients from the molecular and cellular levels. These new strategies will bring hope for the prevention and treatment of glaucoma.
FIGURE 1
New neuroprotective strategy of glaucoma in recent 5 years.
Statements
Author contributions
YX contributed to writing of the manuscript. YJ contributed to manuscript revision.
Funding
This work was supported by the National Natural Science Foundation of China (81600726), Natural Science Foundation of Shandong Province (ZR2016HB53), 2021 Qingdao Medical and Health Scientific Research Project and Youth Science Foundation of the affiliated hospital of Qingdao University.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AiresI. D.BoiaR.Rodrigues-NevesA. C.MadeiraM. H.MarquesC.AmbrosioA. F.et al (2019). Blockade of microglial adenosine A2A receptor suppresses elevated pressure-induced inflammation, oxidative stress, and cell death in retinal cells. Glia67, 896–914. 10.1002/glia.23579
2
BoscoA.AndersonS. R.BreenK. T.RomeroC. O.SteeleM. R.ChiodoV. A.et al (2018). Complement C3-targeted gene therapy restricts onset and progression of neurodegeneration in chronic mouse glaucoma. Mol. Ther.26, 2379–2396. 10.1016/j.ymthe.2018.08.017
3
BusskampV.DuebelJ.BalyaD.FradotM.VineyT. J.SiegertS.et al (2010). Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science329, 413–417. 10.1126/science.1190897
4
CammalleriM.Dal MonteM.AmatoR.BagnoliP.RuscianoD. (2020). A dietary combination of forskolin with homotaurine, spearmint and B vitamins protects injured retinal ganglion cells in a rodent model of hypertensive glaucoma. Nutrients12, E1189. 10.3390/nu12041189
5
de HozR.RamirezA. I.Gonzalez-MartinR.AjoyD.RojasB.Salobrar-GarciaE.et al (2018). Bilateral early activation of retinal microglial cells in a mouse model of unilateral laser-induced experimental ocular hypertension. Exp. Eye Res.171, 12–29. 10.1016/j.exer.2018.03.006
6
DengC.YaoK.PengF.ZhaoB.ChenZ.ChenW.et al (2020). The effect of dietary vitamin K1 supplementation on trabecular meshwork and retina in a chronic ocular hypertensive rat model. Invest. Ophthalmol. Vis. Sci.61, 40. 10.1167/iovs.61.8.40
7
DietzeJ.BlairK.HavensS. J. (2022). Glaucoma. Treasure Island (FL): StatPearls. Treasure Island (FL).
8
DonahueR. J.FehrmanR. L.GustafsonJ. R.NickellsR. W. (2021). BCLXL gene therapy moderates neuropathology in the DBA/2J mouse model of inherited glaucoma. Cell. Death Dis.12, 781. 10.1038/s41419-021-04068-x
9
DongL.HuY.ZhouL.ChengX. (2018). P2X7 receptor antagonist protects retinal ganglion cells by inhibiting microglial activation in a rat chronic ocular hypertension model. Mol. Med. Rep.17, 2289–2296. 10.3892/mmr.2017.8137
10
Ekicier AcarS.SaricaogluM. S.ColakA.AktasZ.Sepici DincelA. (2020). Neuroprotective effects of topical coenzyme Q10 + vitamin E in mechanic optic nerve injury model. Eur. J. Ophthalmol.30, 714–722. 10.1177/1120672119833271
11
FafureA. A.EdemE. E.ObisesanA. O.EnyeL. A.AdekeyeA. O.AdetunjiA. E.et al (2021). Fermented maize slurry (Ogi) and its supernatant (Omidun) mitigate elevated intraocular pressure by modulating BDNF expression and glial plasticity in the retina-gut axis of glaucomatous rats. J. Complement. Integr. Med.0. 10.1515/jcim-2021-0114
12
FangF.ZhuangP.FengX.LiuP.LiuD.HuangH.et al (2022). NMNAT2 is downregulated in glaucomatous RGCs, and RGC-specific gene therapy rescues neurodegeneration and visual function. Mol. Ther.30, 1421–1431. 10.1016/j.ymthe.2022.01.035
13
Ferreira-SilvaJ.AiresI. D.BoiaR.AmbrósioA. F.SantiagoA. R. (2020). Activation of adenosine A(3) receptor inhibits microglia reactivity elicited by elevated pressure. Int. J. Mol. Sci.21, E7218. 10.3390/ijms21197218
14
GiannacciniM.UsaiA.ChielliniF.GuadagniV.AndreazzoliM.OriM.et al (2018). Neurotrophin-conjugated nanoparticles prevent retina damage induced by oxidative stress. Cell. Mol. Life Sci.75, 1255–1267. 10.1007/s00018-017-2691-x
15
GrotegutP.PerumalN.KuehnS.SmitA.DickH. B.GrusF. H.et al (2020). Minocycline reduces inflammatory response and cell death in a S100B retina degeneration model. J. Neuroinflammation17, 375. 10.1186/s12974-020-02012-y
16
GuoX.ZhouJ.StarrC.MohnsE. J.LiY.ChenE. P.et al (2021). Preservation of vision after CaMKII-mediated protection of retinal ganglion cells. Cell.184, 4299–4314.e12. 10.1016/j.cell.2021.06.031
17
GuptaV.ChitranshiN.GuptaV.YouY.RajputR.PauloJ. A.et al (2022). TrkB receptor agonist 7, 8 dihydroxyflavone is protective against the inner retinal deficits induced by experimental glaucoma. Neuroscience490, 36–48. 10.1016/j.neuroscience.2022.01.020
18
HsuehH. T.KimY. C.PithaI.ShinM. D.BerlinickeC. A.ChouR. T.et al (2021). Ion-complex microcrystal formulation provides sustained delivery of a multimodal kinase inhibitor from the subconjunctival space for protection of retinal ganglion cells. Pharmaceutics13, 647. 10.3390/pharmaceutics13050647
19
KeelerA. M.ElMallahM. K.FlotteT. R. (2017). Gene therapy 2017: Progress and future directions. Clin. Transl. Sci.10, 242–248. 10.1111/cts.12466
20
KhatibT. Z.OsborneA.YangS.AliZ.JiaW.ManyakinI.et al (2021). Receptor-ligand supplementation via a self-cleaving 2A peptide-based gene therapy promotes CNS axonal transport with functional recovery. Sci. Adv.7, eabd2590. 10.1126/sciadv.abd2590
21
KimM. L.SungK. R.KwonJ.ChoiG. W.ShinJ. A. (2021). Neuroprotective effect of statins in a rat model of chronic ocular hypertension. Int. J. Mol. Sci.22, 12500. 10.3390/ijms222212500
22
KimY. C.HsuehH. T.ShinM. D.BerlinickeC. A.HanH.AndersN. M.et al (2022). A hypotonic gel-forming eye drop provides enhanced intraocular delivery of a kinase inhibitor with melanin-binding properties for sustained protection of retinal ganglion cells. Drug Deliv. Transl. Res.12, 826–837. 10.1007/s13346-021-00987-6
23
Lani-LouzadaR.MarraC.DiasM. S.de AraújoV. G.AbreuC. A.RibasV. T.et al (2022). Neuroprotective gene therapy by overexpression of the transcription factor MAX in rat models of glaucomatous neurodegeneration. Invest. Ophthalmol. Vis. Sci.63, 5. 10.1167/iovs.63.2.5
24
Livne-BarI.WeiJ.LiuH. H.AlqawlaqS.WonG. J.TuccittoA.et al (2017). Astrocyte-derived lipoxins A4 and B4 promote neuroprotection from acute and chronic injury. J. Clin. Invest.127, 4403–4414. 10.1172/JCI77398
25
LuY.BrommerB.TianX.KrishnanA.MeerM.WangC.et al (2020). Reprogramming to recover youthful epigenetic information and restore vision. Nature588, 124–129. 10.1038/s41586-020-2975-4
26
MaguireA. M.SimonelliF.PierceE. A.PughE. N.Jr.MingozziF.BennicelliJ.et al (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med.358, 2240–2248. 10.1056/NEJMoa0802315
27
MaguireG.EubanksC.AyoubG. (2022). Neuroprotection of retinal ganglion cells in vivo using the activation of the endogenous cannabinoid signaling system in mammalian eyes. Neuronal Signal.6, Ns20210038. 10.1042/ns20210038
28
MeadB.TomarevS. (2017). Bone marrow-derived mesenchymal stem cells-derived exosomes promote survival of retinal ganglion cells through miRNA-dependent mechanisms. Stem Cells Transl. Med.6, 1273–1285. 10.1002/sctm.16-0428
29
OsborneA.KhatibT. Z.SongraL.BarberA. C.HallK.KongG. Y. X.et al (2018). Neuroprotection of retinal ganglion cells by a novel gene therapy construct that achieves sustained enhancement of brain-derived neurotrophic factor/tropomyosin-related kinase receptor-B signaling. Cell. Death Dis.9, 1007. 10.1038/s41419-018-1041-8
30
OswaldJ.KegelesE.MinelliT.VolchkovP.BaranovP. (2021). Transplantation of miPSC/mESC-derived retinal ganglion cells into healthy and glaucomatous retinas. Mol. Ther. Methods Clin. Dev.21, 180–198. 10.1016/j.omtm.2021.03.004
31
RamirezA. I.de HozR.Salobrar-GarciaE.SalazarJ. J.RojasB.AjoyD.et al (2017). The role of microglia in retinal neurodegeneration: Alzheimer's disease, Parkinson, and glaucoma. Front. Aging Neurosci.9, 214. 10.3389/fnagi.2017.00214
32
RaticanS. E.OsborneA.MartinK. R. (2018). Progress in gene therapy to prevent retinal ganglion cell loss in glaucoma and leber's hereditary optic neuropathy. Neural Plast.2018, 7108948. 10.1155/2018/7108948
33
ShenJ.XiaoR.BairJ.WangF.VandenbergheL. H.DarttD.et al (2018). Novel engineered, membrane-localized variants of vascular endothelial growth factor (VEGF) protect retinal ganglion cells: A proof-of-concept study. Cell. Death Dis.9, 1018. 10.1038/s41419-018-1049-0
34
SmalleyE. (2017). First AAV gene therapy poised for landmark approval. Nat. Biotechnol.35, 998–999. 10.1038/nbt1117-998
35
SomvanshiR. K.ZouS.KadhimS.PadaniaS.HsuE.KumarU. (2022). Cannabinol modulates neuroprotection and intraocular pressure: A potential multi-target therapeutic intervention for glaucoma. Biochim. Biophys. Acta. Mol. Basis Dis.1868, 166325. 10.1016/j.bbadis.2021.166325
36
StothertA. R.KaurT. (2021). Innate immunity to spiral ganglion neuron loss: A neuroprotective role of fractalkine signaling in injured cochlea. Front. Cell. Neurosci.15, 694292. 10.3389/fncel.2021.694292
37
SuenH. C.QianY.LiaoJ.LukC. S.LeeW. T.NgJ. K. W.et al (2019). Transplantation of retinal ganglion cells derived from male germline stem cell as a potential treatment to glaucoma. Stem Cells Dev.28, 1365–1375. 10.1089/scd.2019.0060
38
TianF.ChengY.ZhouS.WangQ.MonavarfeshaniA.GaoK.et al (2022). Core transcription programs controlling injury-induced neurodegeneration of retinal ganglion cells. Neuron110, 2607–2624.e8. 10.1016/j.neuron.2022.06.003
39
VisuvanathanS.BakerA. N.LagaliP. S.CouplandS. G.MillerG.HauswirthW. W.et al (2022). XIAP gene therapy effects on retinal ganglion cell structure and function in a mouse model of glaucoma. Gene Ther.29, 147–156. 10.1038/s41434-021-00281-7
40
WangH.YangY.LiuJ.QianL. (2021). Direct cell reprogramming: Approaches, mechanisms and progress. Nat. Rev. Mol. Cell. Biol.22, 410–424. 10.1038/s41580-021-00335-z
41
WangQ.ZhuangP.HuangH.LiL.LiuL.WebberH. C.et al (2020). Mouse γ-synuclein promoter-mediated gene expression and editing in mammalian retinal ganglion cells. J. Neurosci.40, 3896–3914. 10.1523/jneurosci.0102-20.2020
42
Wojcik-GryciukA.Gajewska-WozniakO.KordeckaK.BoguszewskiP. M.WaleszczykW.SkupM. (2020). Neuroprotection of retinal ganglion cells with AAV2-BDNF pretreatment restoring normal TrkB receptor protein levels in glaucoma. Int. J. Mol. Sci.21, E6262. 10.3390/ijms21176262
43
XiaoD.JinK.QiuS.LeiQ.HuangW.ChenH.et al (2021). In vivo regeneration of ganglion cells for vision restoration in mammalian retinas. Front. Cell. Dev. Biol.9, 755544. 10.3389/fcell.2021.755544
44
YuH.ZhongH.LiN.ChenK.ChenJ.SunJ.et al (2021). Osteopontin activates retinal microglia causing retinal ganglion cells loss via p38 MAPK signaling pathway in glaucoma. FASEB J.35, e21405. 10.1096/fj.202002218R
45
YuZ.WenY.JiangN.LiZ.GuanJ.ZhangY.et al (2022). TNF-α stimulation enhances the neuroprotective effects of gingival MSCs derived exosomes in retinal ischemia-reperfusion injury via the MEG3/miR-21a-5p axis. Biomaterials284, 121484. 10.1016/j.biomaterials.2022.121484
46
ZhangJ.WuS.JinZ. B.WangN. (2021). Stem cell-based regeneration and restoration for retinal ganglion cell: Recent advancements and current challenges. Biomolecules11, 987. 10.3390/biom11070987
47
ZhangX.TohariA. M.MarcheggianiF.ZhouX.ReillyJ.TianoL.et al (2017). Therapeutic potential of Co-enzyme Q10 in retinal diseases. Curr. Med. Chem.24, 4329–4339. 10.2174/0929867324666170801100516
48
ZhangX.ZhangN.ChrenekM. A.GirardotP. E.WangJ.SellersJ. T.et al (2021). Systemic treatment with Nicotinamide riboside is protective in two mouse models of retinal ganglion cell damage. Pharmaceutics13, 893. 10.3390/pharmaceutics13060893
Summary
Keywords
retinal ganglion cells, glaucoma, neuroprotection, gliocyte, gene therapy
Citation
Xuejiao Y and Junwei Y (2022) New strategies for neuro protection in glaucoma. Front. Cell Dev. Biol. 10:983195. doi: 10.3389/fcell.2022.983195
Received
30 June 2022
Accepted
30 August 2022
Published
15 September 2022
Volume
10 - 2022
Edited by
Wei Qiu, Third Affiliated Hospital of Sun Yat-sen University, China
Reviewed by
Ling Zhao, Zhongshan Ophthalmic Center, Sun Yat-sen University, China
Updates
Copyright
© 2022 Xuejiao and Junwei.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yang Xuejiao, yxj5211@163.com
This article was submitted to Molecular and Cellular Pathology, a section of the journal Frontiers in Cell and Developmental Biology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.